Neurol. praxi. 2020;21(6):466-471

Diabetic polyneuropathy treatment

MUDr. Milan Grofik, PhD.1, MUDr. Michal Cibulka, PhD.2, prof. MUDr. Egon Kurča, PhD., FESO1
1 Neurologická klinika, Jesseniova lekárska fakulta UK a Univerzitná nemocnica, Martin
2 BioMed - Martinské centrum pre biomedicínu, Jesseniova lekárska fakulta UK, Martin

Diabetic polyneuropathy is the most frequent complication of diabetes mellitus and at the same time the most common cause of diabetic foot syndrome and pain in patients with diabetes. This disorder is still being diagnosed insufficiently and too late in many cases. Therapeutic intervention in early stages could slow down (or completely stop) progression of the neuropathy. Presented paper reviews current possibilities of prevention and therapy of diabetic polyneuropathy as well as pharmaceuticals and nutraceuticals that were, or still are involved in clinical trials.

Keywords: diabetic polyneuropathy, neuropatic pain.

Received: September 12, 2020; Revised: September 28, 2020; Accepted: October 14, 2020; Prepublished online: October 14, 2020; Published: January 6, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Grofik M, Cibulka M, Kurča E. Diabetic polyneuropathy treatment. Neurol. praxi. 2020;21(6):466-471.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24): 2560-2572. Go to original source... Go to PubMed...
    2. Alvarez M, Rincón Sierra O, Saavedra G, and Moreno S. Vitamin B12 deficiency and diabetic neuropathy in patients taking metformin: A cross-sectional study. Endocrine Connections 2019; 8(10): 1324-1329. Go to original source... Go to PubMed...
    3. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2009 revision. European Journal of Neurology 2010; 17(9): 1113-e88. Go to original source... Go to PubMed...
    4. Bednařík J, Ambler Z, Opavský J, Keller O, Rokyta R, Mazanec R, Lejčko J, Kozák J, Suchý M, Pátá M, Kožený P. Klinický standard pro farmakoterapii neuropatické bolesti. Cesk Slov Neurol N 2012; 75/108(1): 93-101.
    5. Bril V, England J, Franklin G, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson DJ, Perkins B, Russell JW, Zochodne D, American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, & American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: treatment of painful diabetic neuropathy. Neurology 2011; 76(20): 1758-1765. Go to original source... Go to PubMed...
    6. Chu C, Zhao W, Zhang Y, Li L, Lu J, Jiang L, Wang C, Jia W. Low serum magnesium levels are associated with impaired peripheral nerve function in type 2 diabetic patients. Sci Rep 2016; 6(1): 32623. Go to original source... Go to PubMed...
    7. De Leeuw I, Engelen E, De Block C, Van Gaal L. Long term magnesium supplementation influences favourably the natural evolution of neuropathy in Mg-depleted type 1 diabetic patients (T1DM). Magnes Res 2004; 17(2): 109-114.
    8. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015; 14(2): 162-173. Go to original source... Go to PubMed...
    9. Freo U, Romualdi P, Kress HG. Tapentadol for neuropathic pain: a review of clinical studies. J Pain Res 2019; 12: 1537-1551. Go to original source... Go to PubMed...
    10. Gazoni FM, Malezan WR, Santos FC. B complex vitamins for analgesic therapy. Revista Dor 2016; 17(1): 52-56. Go to original source...
    11. Hajaš G. Diabetická polyneuropatia. Neurol. praxi 2018; 19(3): 161-171. Go to original source...
    12. Haupt E, Ledermann H, Köpcke W. Benfotiamine in the treatment of diabetic polyneuropathy - a three-week randomized, controlled pilot study (BEDIP Study). Int J Clin Pharmacol Ther 2005; 43(02): 71-77. Go to original source... Go to PubMed...
    13. Heidari N, Sajedi F, Mohammadi Y, Mirjalili M, Mehrpooya M. Ameliorative effects of N-acetylcysteine as adjunct therapy on symptoms of painful diabetic neuropathy. Journal of Pain Research 2019; 12: 3147-3159. Go to original source... Go to PubMed...
    14. Jann S, Fazio R, Cocito D, Toscano A, Schenone A, Marfia GA, Antonini G, De Toni Franceschini L, Mazzeo A, Grandis M, Velardo D, Mataluni G, Peci E. High-dose intravenous immunoglobulin is effective in painful diabetic polyneuropathy resistant to conventional treatments. Results of a double-blind, randomized, placebo-controlled, multicenter trial. Pain Medicine 2020; 21 (3): 576-585. Go to original source... Go to PubMed...
    15. Kluding PM, Pasnoor M, Singh R, Jernigan S, Farmer K, Rucker J, Sharma NK, Wright DE. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. Journal of Diabetes and Its Complications 2012; 26 (5): 424-429. Go to original source... Go to PubMed...
    16. Moisset X, Bouhassira D, Avez Couturier J, Alchaar H, Conradi S, Delmotte MH, Lanteri-Minet M, Lefaucheur JP, Mick G, Piano V, Pickering G, Piquet E, Regis C, Salvat E, Attal N. Pharmacological and nonpharmacological treatments for neuropathic pain: systematic review and French recommendations. Rev Neurol. 2020; 176(5): 325-352. Go to original source... Go to PubMed...
    17. Papanas N, Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother 2014; 15(18): 2721-2731. Go to original source... Go to PubMed...
    18. Popa AR, Bungau S, Vesa CM, Bondar AC, Pantis C, Maghiar O, Dimulescu IA (Nica), Cseppento DCN, Rus M. Evaluating the eficacy of the treatment with benfotiamine and alpha-lipoic acid in distal symmetric painful diabetic polyneuropathy. Revista de Chimie 2019; 70(9): 3108-3114. Go to original source...
    19. Ramirez MA, Borja NL. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy 2008: 28(5): 646-655. Go to original source... Go to PubMed...
    20. Rolim LC, da Silva EM, Flumignan RL, Abreu MM, Dib SA. Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews 2019; 6(6): CD011265. Go to original source... Go to PubMed...
    21. Ropper AH, Gorson KC, Gooch CL, Weinberg DH, Pieczek A, Ware JH, Kershen J, Rogers A, Simovic D, Schratzberger P, Kirchmair R, Losordo D. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Annals of neurology 2009; 65(4): 386-393. Go to original source... Go to PubMed...
    22. Simpson DM, Robinson-Papp J, Van J, Stoker M, Jacobs H, Snijder RJ, Schregardus DS, Long SK, Lambourg B, Katz N. Capsaicin 8 % Patch in Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study. J Pain 2017; 18(1): 42-53. Go to original source... Go to PubMed...
    23. Singleton JR, Marcus RL, Jackson JE, K Lessard M, Graham TE, Smith AG. Exercise increases cutaneous nerve density in diabetic patients without neuropathy. Ann Clin Transl Neurol 2014; 1(10): 844-849. Go to original source... Go to PubMed...
    24. Smith AG, Russell J, Feldman EL, Goldstein J, Peltier A, Smith S, Hamwi J, Pollari D, Bixby B, Howard J, Singleton JR. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 2006; 29(6): 1294-1299. Go to original source... Go to PubMed...
    25. Stino AM, Smith AG. Peripheral neuropathy in prediabetes and the metabolic syndrome. J Diabetes Investig 2017; 8(5): 646-655. Go to original source... Go to PubMed...
    26. Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008; 116(10): 600-605. Go to original source... Go to PubMed...
    27. Stracke H, Lindemann A, Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes 1996; 104(4): 311-316. Go to original source... Go to PubMed...
    28. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122(8): 561-568. Go to original source... Go to PubMed...
    29. Wahren J, Foyt H, Daniels M, Arezzo JC. Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes: A 12-Month Clinical Trial. Diabetes Care 2016; 39(4): 596-602. Go to original source... Go to PubMed...
    30. Wolff RF, Bala MM, Westwood M, Kessels AG, Kleijnen J. 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly 2010; 140(21-22): 297-306. Go to original source... Go to PubMed...
    31. Yang XD, Fang PF, Xiang DX, Yang YY. Topical treatments for diabetic neuropathic pain. Exp Ther Med 2019; 17(3): 1963-1976. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.